BridgeBio's acoramidis beats rival drug in real-world heart study
BridgeBio Pharma (BBIO) said its heart drug acoramidis outperformed tafamidis in a new peer-reviewed, real-world study of patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and progressive disease of the heart muscle.
